Enjoy complimentary customisation on priority with our Enterprise License!
The Antibody Drug Conjugates (ADC) Market size is estimated to grow by USD 9.95 billion at a CAGR of 15.06% between 2023 and 2028.
There has been an increasing prevalence of cancer and other diseases across the world. In addition, the antibody drug conjugates (ADCs) market is expanding quickly in North America. Moreover, ADCs are a family of targeted cancer medicines that combine cytotoxic drugs that kill cancer cells with monoclonal antibodies, which target particular cancer cells. In addition, the presence of a significant number of pharmaceutical companies, a well-established healthcare infrastructure, and advantageous reimbursement policies contribute to North America dominant position in the global antibody drug conjugates market. Hence, such factors are positively impacting the market.
Technavio has segmented the market into Application, Technology, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
Breast cancer
The breast cancer segment is estimated to witness significant growth during the forecast period. This segment is one that is both significant and expanding quickly within the global antibody drug conjugates (ADC) market. ADCs refer to a class of targeted cancer therapy that combines the cytotoxic qualities of chemotherapeutic medicines with the specificity of monoclonal antibodies.
Get a glance at the market contribution of various segments Download PDF Sample
The breast cancer segment was the largest segment and was valued at USD 3.22 billion in 2018. Moreover, breast cancer is one of the most prevalent cancers worldwide, especially in women. In addition, it is linked to a high rate of morbidity and is responsible for a sizable portion of cancer-related fatalities. Therefore, it is crucial to establish efficient and focused breast cancer therapy choices. Furthermore, ADCs provide a viable alternative for treating breast cancer as they target cancer cells specifically and deliver cytotoxic medicines straight to the tumor site. In addition, this targeted delivery reduces the potential side effects associated with traditional chemotherapy, such as damage to healthy cells and tissues. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
The cleavable linker segment is a major component of the global antibody drug conjugates market. In addition, ADCs are a brand-new family of targeted therapeutic agents that combine small-molecule medicinal potency with the specificity of monoclonal antibodies (MAbs). Moreover, the ability to selectively release the drug inside the intended cancer cell is made possible by the cleavable linker, which connects the cytotoxic payload (drug) and the antibody. In addition, the cleavable linker is intended to cleave effectively and selectively in the target cell to enable successful drug delivery, but it should also be stable in circulation to prevent premature drug release. .Furthermore, advanced cleavable linkers are witnessing increasing demand as ADC development moves forward. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 50% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The antibody drug conjugates (ADCs) market is expanding quickly in North America due to the factors such as the presence of a significant number of pharmaceutical companies, a well-established healthcare infrastructure, and advantageous reimbursement policies. In addition, ADCs are a family of targeted cancer medicines that combine cytotoxic drugs that kill cancer cells with monoclonal antibodies, which target particular cancer cells. Moreover, due to its modern healthcare facilities and the high prevalence of cancer, the US accounts for the biggest market share in North America. The region's rising cancer incidence rate, increased investments in the biopharmaceutical industry, and an increase in research and development efforts are driving the market growth in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AbbVie Inc: The company offers an antibody drug conjugate that consists of a cytotoxin covalently linked to a monoclonal antibody that recognizes an antigen differentially overexpressed on tumor cells.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
A key factor shaping the antibody drug conjugates market growth is the increasing adoption and development of targeted therapies. There has been an increasing acceptance and development of targeted therapies, which is a notable trend in the global antibody drug conjugates market. In addition, ADCs, or antibody drug conjugates, are a family of biopharmaceutical medications that target cancer cells specifically with deadly chemicals by using monoclonal antibodies.
Moreover, pharmaceutical firms and medical experts are taking notice of these innovative drugs as they appear to be effective in treating a variety of cancers. In addition, growing knowledge of the underlying molecular pathways of cancer progression is one of the key drivers propelling the use of targeted therapies. Hence, such factors are positively impacting the antibody drug conjugates (ADC) market. Therefore, it is expected to drive the market growth during the forecast period.
High development costs for antibody drug conjugates are one of the key challenges hindering the antibody drug conjugates market growth. The global antibody drug conjugates market is facing high development costs, which poses a major challenge to market growth. In addition, ADCs are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy drugs.
Moreover, developing and manufacturing ADCs involves multiple complex processes, making it a costly endeavor. For instance, it takes a lot of research and development to create an ADC, including choosing appropriate targets, creating the antibody, and attaching it to the cytotoxic agent. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Antibody Drug Conjugates Market Customer Landscape
The antibody drug conjugates market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
|
Antibody Drug Conjugates Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
156 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 15.06% |
|
Market Growth 2024-2028 |
USD 9.95 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
14.35 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 50% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Adcendo ApS, Araris Biotech AG, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., ImmunoGen Inc., Merck KGaA, Mersana Therapeutics Inc., Mythic Therapeutics, Pfizer Inc., Piramal Enterprises Ltd., PPF Group, Regeneron Pharmaceuticals Inc., Seagen Inc., Syngene International Ltd., Takeda Pharmaceutical Co. Ltd., and ADC Therapeutics SA |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
